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Abstract  
Escherichia coli is the workhorse for gene cloning and production of soluble 
recombinant proteins in both biotechnological and biomedical industries. The bacterium 
is also a good producer of several classes of protein-based self-assembling materials 
such as inclusion bodies (IBs). Apart from being a relatively pure source of protein for 
in vitro refolding, IBs are under exploration as functional, protein-releasing materials in 
regenerative medicine and protein replacement therapies. Endotoxin removal is a 
critical step for downstream applications of therapeutic proteins. The same holds true 
for IBs as they are often highly contaminated with cell-wall components of the host 
cells. Here we have investigated the production of IBs in a recently developed 
endotoxin-free E. coli strain. The characterization of IBs revealed this mutant as a very 
useful cell factory for the production of functional endotoxin-free IBs that are suitable 
for the use at biological interfaces without inducing endotoxic responses in human 
immune cells. 
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Introduction 
Recombinant proteins produced in the Gram-negative bacterium Escherichia coli tend 
to be deposited as insoluble protein clusters known as inclusion bodies (IBs). These 
protein particles, ranging from 50 to around 500 nm in diameter, are emerging protein 
materials with intriguing biomedical applications (Garcia-Fruitos et al. 2011; Villaverde 
et al. 2012; Villaverde 2012), that can be regarded as biomimetics of functional 
amyloids (protein repositories for sustained release) acting in the endocrine system 
(Maji et al. 2009; Badtke et al. 2009; Mankar et al. 2011; Cano-Garrido et al. 2013). 
Bacterial IBs show high biological activity (Garcia-Fruitos et al. 2005; Gonzalez-
Montalban et al. 2007; Garcia-Fruitos et al. 2012), spontaneous penetrability in 
mammalian cells (Vazquez et al. 2012) and also mechanical and biological stability 
(Diez-Gil et al. 2010; García-Fruitós et al. 2009), which has allowed to adapt them as 
nanostructured materials for surface decoration in tissue engineering (García-Fruitós et 
al. 2009; Seras-Franzoso et al. 2013b; Tatkiewicz et al. 2013; Diez-Gil et al. 2010; 
Seras-Franzoso et al. 2011; Seras-Franzoso et al. 2012; Seras-Franzoso J et al. 2013) 
and in the context of top-down and bottom-up protein replacement/delivery cell 
therapies (Vazquez et al. 2012; Cano-Garrido et al. 2013; Talafova et al. 2013; Liovic 
et al. 2012). However, these applications require the bacterial product being free of E. 
coli-derived lipopolysaccharide (LPS) that is capable of inducing an endotoxic immune 
response in humans and other mammals. If present, these bacterial contaminants can 
severely restrict the biomedical applicability of the material. So far, the efforts 
addressed to obtain pure IBs have been focussed on the development of optimized 
cell-disruption methods for the isolation of these sub-micron particles lacking bacterial 
cells (Rodriguez-Carmona et al. 2010). However, the preparation of cell-free IBs, while 
preventing further bacterial contamination, does not guarantee the absence of free or 
IB-associated LPS. In fact, cell-wall contaminants are believed to associate with IBs 
during the disruption and separation processes (Georgiou and Valax 1999). In the 
present study, we have therefore addressed the question of functional IB production in 
a recently developed endotoxin-free E. coli strain, in order to overcome limitations 
caused by the potential presence of endotoxin in IB preparations. 
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Material and methods 
Strains, media and plasmids 
The E. coli K-12 strains used in this study were MC4100 ([araD139], (argF-lac)169, λ- 
relA1, rpsL150, rbsR22, flb5301, deoC1, pstF25 StrepR), BW30270 (CGSC#7925 - 
MG1655; F-, rph+, fnr+) and its isogenic endotoxin-free strain KPM335 (msbA52, ΔgutQ, 
ΔkdsD, ΔlpxL, ΔlpxM, ΔpagP, ΔlpxP, ΔeptA, frr181). KPM335 will be described in detail 
elsewhere. All these strains were transformed with pTr99a-VP1GFP (ApR) encoding the 
fusion protein VP1GFP, an aggregation-prone fluorescent protein previously used as a 
reporter to study IB formation (Garcia-Fruitos et al. 2007). Both transformed and 
plasmid-free E. coli strains were cultured in Luria-Bertani (LB Miller) media 
(J.Sambrook et al. 1989).  
 
Competent cells  
Overnight cultures of MC4100 and BW32070 grown at 37ºC and 250 rpm were used as 
a 1/100 inoculum in 50 ml of LB. When the cells reached the early exponential growth 
phase at an optical density (OD550) between 0.2 - 0.4 at 37ºC, 25-ml aliquots of the 
cultures were centrifuged (4,000 x g) at 4 ºC for 15 min. Pellets were resuspended in 
12.5 ml of cold and sterile 50 mM CaCl2 and left for 45 min in an ice bath. Cells were 
centrifuged again under the same conditions as described above and resuspended in 
1.25 ml of cold and sterile 50 mM CaCl2. Finally, aliquots of 200 µl in CaCl2 / glycerol 
(15 % v/v) were stored at -80ºC. 
 
Electrocompetent cells 
KMP335 cells were grown overnight at 37ºC and 250 rpm and diluted 1/50 in 80 ml of 
LB. The cells were grown to an OD550 between 0.2 - 0.4, placed on ice for 20 min and 
sedimented by centrifugation (3100 x g, 4 ºC, 20 min). The bacterial cells were washed 
successively in 40, 20 and 10 ml of H2O (ice-cold and sterile), followed by an additional 
washing step in 5 ml of 10% glycerol (ice-cold and sterile), resuspension of the final cell 
sediment in 1 ml of 10% glycerol (ice-cold and sterile), and preparation of 50-µl aliquots 
for electroporation. 
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Transformation 
Transformation of competent MC4100 and BW32070 cells was performed using 40 ng 
of plasmid DNA. The transformation mixtures were incubated on ice for 30 - 60 min and 
then warmed up to 42ºC for 45 sec. The mixtures were then immediately placed on ice 
for 30 sec, and 800 µl of LB were added, followed by incubation of the transformed 
cells at 37°C for 1 h. Cells were plated on LB-agar plates containing ampicillin (100 
µg/ml) and incubated overnight at 37ºC. KPM335 cells were transformed by 
electroporation in a pre-chilled 0.2-cm gap electroporation cuvette using 50 µl of 
competent cells and 40 ng of plasmid DNA. Cells were pulsed using a Gene Pulser MX 
cell electroporator (Bio-Rad, Hercules, CA, USA) at 25 µF, 200 Ω, 2,500 V and  4.7 - 
4.8 msec. Immediately after the pulse, 800 µl of LB medium were added, and the 
mixture was incubated at 37°C for 1 h. The culture was plated on LB-agar plates 
containing ampicillin (100 µg/ml) and incubated at 37°C overnight.  
 
Protein production 
VP1GFP was produced at three growth temperatures (37ºC, 25ºC and 16ºC). 
Overnight cultures were inoculated each in triplicate in three 250-ml shake flasks 
containing 50 ml of LB media with 100 µg/ml ampicillin (plus 30 µg/ml streptomycin in 
MC4100) and incubated at 37ºC and 250 rpm until the cells reached the mid-
exponential growth phase between 0.5 and 0.6 OD550 units. Recombinant gene 
expression was then induced by the addition of IPTG to a final concentration of 1 mM. 
Cultures were then incubated for either 3h at 37ºC or overnight at 25°C and 16ºC.  At 
the indicated times, 20 ml of each culture were harvested by centrifugation (10,000 x g, 
4ºC, 10 min). The pellets were resuspended in 1 ml PBS containing the Complete 
EDTA-free protease inhibitor cocktail (Roche Diagnostics, Indianapolis, USA). Cells 
were disrupted by 5-min cycles and pulses of 0.5 seconds (power at 40 %) using a Lab 
Sonic ultrasonicator (B. Braun, Mesulgen, Germany). Each cell lysate was separated 
into two aliquots of 500 µl for protein quantification by Western blot analysis and 
fluorescence measurement. Aliquots of the IB samples were centrifuged (15,000 g,  
4ºC, 15 min), and both the IB pellets and the supernatants were stored at -20ºC.  
 
IB purification 
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Overnight cultures of MC4100, BW32070 and KPM335 grown at 37ºC and 250 rpm 
were used as a 1/100 inoculum in 500-ml of LB and VP1GFP IBs were produced at 37 
ºC. After production, Lysozyme (1 µg/ml), phenylmethylsulfonyl fluoride (0.4mM) and 
EDTA-free protease inhibitor cocktail (Complete EDTA-free Roche Diagnostics, 
Indianápolis, USA) were added and cultures were incubated for 2 h at 37ºC and 250 
rpm. Mixtures were stored at -80ºC. Cultures were thawed at room temperature, and 2 
ml of Triton X-100 (Roche Diagnostics, Indianapolis, USA) were added and left at room 
temperature for 1 h. As a bacterial viability control, 100 µl of the culture were plated on 
LB-agar without antibiotics, and the samples were stored again at -80ºC. Freeze-thaw 
cycles were repeated until no colony was found on the plates. Once the absence of 
viable bacteria was confirmed, 125 µl of nonyl phenoxypolyethoxylethanol (NP-40) 
(Roche Diagnostics, Indianapolis, USA) were added, followed by incubation of the 
samples at 4ºC for 1 h. After incubation, MgSO4 0.6 M and DNase 0.6 µg/ml were 
added (Roche Diagnostics, Indianapolis, USA). The samples were incubated at 37ºC 
for 1 h with shaking and centrifuged (15,000 x g, 4ºC, 15 min). The pellets were 
subsequently resuspended with 25 ml of lysis buffer (50 mM Tris HCl, pH 8.0, 100 mM 
NaCl, 1 mM EDTA containing 0.5% Triton X-100) containing 0.5 % Triton X-100 
(Roche Diagnostics, Indianapolis, USA). 100 µl of each sample were plated on LB-agar 
without antibiotics, and the plates were incubated at 37ºC overnight. The samples were 
centrifuged again under the same conditions as described above. The pellets were 
resuspended in PBS, and 100 µl-aliquots were plated to monitor bacterial viability. 
Finally, the resuspended pellets containing the IBs were separated into 5-ml aliquots 
and sedimented again by centrifugation (15,000 x g, 4ºC, 15 min). The supernatants 
were discarded, and the pellets were stored at -80 ºC.  
 
SDS-PAGE and Western blot analysis 
Protein quantification was performed by sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using 10% polyacrylamide gels according to Laemmli’s 
method (Laemmli 1970). For quantification, the GFP-H6 protein at 500, 250, 125, 75 
and 37.5 ng (Vazquez et al. 2010) was used as a standard on each gel. Soluble protein 
samples were denatured by incubation at 98ºC for 5 minutes, whereas IBs were 
incubated for 40 min. For Western blot analyses, protein samples were 
electrotransferred to nitrocelulose membranes (GE Healthcare, Buckinghamshire, 
England) using 10% glycine, 20% methanol in H2O as a transfer buffer. The 
membranes were blocked with 5% milk powder in PBS overnight, followed by 
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incubation of the membranes with anti-GFP antibody as recommended by the 
manufacturer (sc-8334, Santa Cruz Biotechnology, CA, USA). HRP-conjugated anti-
rabbit IgG  (H+L) antibody (Bio-Rad, Hercules, CA, USA) at a dilution of 1/2000 was 
used as a secondary antibody. The membranes were developed in a solution 
consisting of 25% cold methanol, 0.2% H2O2 and 0.65 mg/ml of 4-chloronaftol in PBS. 
Images of the membranes were obtained using a GS800 Calibrated Densitometer 
scanner (Bio-Rad, Hercules, CA, USA). The protein amount of the bands was analyzed 
from the standard curve fitting equation of GFP-H6 using the Quantity One software. 
 
Determination of GFP fluorescence  
To determine the fluorescence of GFP, IBs were resuspended in 1 ml PBS, whereas 
supernatants (0.5 ml of soluble protein) were mixed with 0.5 ml PBS. Measurements 
were performed in a fluorescence spectrometer Cary Eclipse (Varian, Mulgrave 
Australia) using 1-ml cuvettes at 450 nm of excitation wavelength and 510 nm of 
emission wavelength. 
 
Statistical analysis 
The data were analyzed using a GLM model under a completely randomized design 
with a factorial array of 4 x 3 (4 strains x 3 production temperatures) according to the 
following equation:  
Yij= µ + αi + βj + (αiβj) + Eij 
Where:  
Yij = Protein quantity, fluorescence, specific fluorescence (soluble and IBs)  
µ = Total mean of each variable  
αi: = Strain effect  
βj = Temperature effect 
(αiβj) = Interaction strain-temperature effect 
Eij= Experimental Error 
Moreover, a least square comparison test of each production was made for all 
variables. 
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Light microscopy  
For visualization of bacterial cells and IBs, 1 ml of each sample was centrifuged at 
10,000 x g and 4ºC for 10 min. Pellets were resuspended in 1 ml of 0.1 % 
formaldehyde in PBS. Images were examined at 100 x magnification in the dark field 
with fluorescence and phase contrast using a Leica DRMB microscope (Leica 
Microsystems, Wetzlar, Germany). Images were digitalized using the Leica LAS 3.0 
software. 
 
Scanning electron microscopy 
Purified IBs were resuspended in PBS-Tween-20 buffer and filtered using a 0.2 µm 
Nucleopore Whatman membrane (GE Healthcare, Buckinghamshire, England). 
Membranes were fixed with 2.5 % glutaraldehyde-phosphate at 4ºC for 1 h. After fixing, 
the samples were dehydrated through sequential washes with ethanol (Sharlau 
Microbiologics, Barcelona, Spain) at increasing concentrations from 50 to 99 % during 
15-30 min. Remaining Ethanol was evaporated in a K850 CDP desiccator (Emitech, 
Ashford, UK), and dry membranes were covered with gold using a Sputter Coater k550 
(Emitech, Ashford, UK). Examination of the specimens was performed at accelerations 
between 0.5 and 30 kV using a Hitachi s-570 scanning electron microscope (Hitachi 
Ltd, Tokio, Japan). 
 
Cell proliferation assay 
Human skin fibroblast cells (1BR3.G) were grown at 37ºC and 10% CO2 on IB-
decorated surfaces. For that, 1 µg of VP1GFP IBs were added to each well of an 
untreated Costar 3370 plate and incubated with Dulbecco’s Modified Eagle’s Medium 
(DMEM) at 4ºC overnight. After incubation, the medium was replaced, and non-
attached IBs were washed out three times using 200 ml of filtered and sterile PBS. 
1BR3.G cells were added (5,000 cells per well) in DMEM medium with 2% of Fetal 
Bovine Serum (FBS). Plates were incubated at 37 ºC for 24, 48 and 72 hours, and the 
MTT proliferation cell assay was performed using the Nonradioactive Cell Proliferation 
and Cytotocity Assay Kit EZ4U as recommended by the manufacturer (Biomedica 
Medizinprodukte GmbH, Wien, Austria). Absorbance was measured in a multilabel 
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reader VICTOR3 V1420 (Perkin Elmer) at 450 nm (and 620 nm as reference), and the 
values were standardized with respect to the negative control. 
 
IB internalization test  
HeLa cells (60,000 cells per well) were seeded in treated 12 well plates (Nunclon 
surface, Nunc 150628) in the presence of MEM-α medium supplemented with 10% 
FBS and 2 mM Glutamax (Gibco, Rockville MD) . After incubation at 37ºC and 5% CO2 
for 24 h, the medium was removed, and the cells were washed with DPBS. Then, 5 µg 
of VP1GFP IBs were suspended in MEM-α containing 10% FBS and 2 mM Glutamax, 
and added per well. After 48h, cell samples were treated with trypsin (1 mg/ml) in 
DPBS for 15 min, and samples were analyzed on a FACSCanto system (Becton 
Dickinson) using a 15 W air-cooled argon-ion laser at 488 nm excitation for GFP. 
Fluorescence emission was measured with a 530/30 nm band pass filter  
 
LPS detection assay 
The LPS detection assay using tenfold serial dilution steps of VP1GFP IBs was 
performed with HEK-Blue™ hTLR4 cells in accordance with the specifications of the 
supplier of the cell lines (InvivoGen, Toulouse, France). HEK-Blue™ Null2, the parental 
cell line of HEK-Blue™ hTLR4, was used as a control. 
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Results 
To investigate the formation of IBs by the aggregation-prone VP1GFP protein, wild-
type and endotoxin-free E. coli strains carrying the pTr99a-VP1GFP plasmid were 
grown aerobically in LB medium containing 100 µg/ml ampicillin at 37°C, 25°C and 
16°C. As shown in Figure 1, the optical densities at 550 nm (OD550) of all cultures 
following induction of recombinant gene expression for three hours did not differ 
considerably from each other, although the endotoxin-free strain KPM335 consistently 
reached lower OD550 values than its parental wild-type strain BW30270 and the 
MC4100 control strain at all three temperatures. 
Production and separation of VP1GFP into soluble and insoluble fractions revealed that 
the amounts of recombinant VP1GFP obtained from MC4100 and BW30270 were 
usually similar, but about twice the amount than in the endotoxin-free strain KPM335 at 
37ºC (Fig. 2). In KPM335, the total amount of soluble VP1GFP was higher than in wild 
type strains. Strikingly, no insoluble protein was detected in KPM335 at 16ºC. The 
intensity of GFP fluorescence of both the soluble and the insoluble fraction (Fig. 3A) 
was in accord with the protein amount obtained from the E. coli strains (Fig. 2). As 
expected, specific fluorescence of insoluble VP1GFP was in general lower than that of 
the soluble protein, with very low levels in MC4100 and BW30270 at 37ºC (Fig. 3B). As 
a general trend, specific fluorescence of the soluble protein increased with lower 
culture temperatures, indicative of improved protein folding. 
Interestingly, insoluble VP1GFP produced in KPM335 showed the highest specific 
fluorescence at each temperature when compared with the insoluble fraction from the 
wild-type strains (Fig. 3B), suggesting a higher conformational and, therefore, 
functional quality of IBs produced in the LPS-free strain. this fact could be of 
bionanotechnological relevance if in this strain, the insoluble protein is organized as 
inclusion bodies (IBs). IBs, as sub-micron protein particles, are gaining relevance in 
biotechnology (Garcia-Fruitos et al. 2012) and biomedicine (Vazquez and Villaverde 
2013) because of their penetrability in mammalian cells in absence of toxicity and their 
ability to release therapeutic proteins inside receiving cells, in either substitutive protein 
therapies (Liovic et al. 2012; Talafova et al. 2013; Vazquez et al. 2012) or in tissue 
engineering (Seras-Franzoso J et al. 2013; Cano-Garrido et al. 2013; Seras-Franzoso 
et al. 2013b; Seras-Franzoso et al. 2013a). Interestingly, they act as natural 
biomimetics of hormone-releasing secretory granules of the endocrine system 
(Villaverde 2012), what offers a plethora of therapeutic opportunities.  
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The formation of fluorescent IBs in KPM335 was confirmed by light microscopy (Fig. 
4C). Like IBs produced in MC4100 and BW30270 (Figs. 4A and 4B) and commonly 
observed in IB-producing bacteria (Villaverde and Carrio 2003), the IBs in KPM335 
appeared as refractile particles adopting a polar distribution. The fluorescent intensity 
was also highest here in KPM335 (Fig. 4C) and, thus, in good agreement with 
measurements using fluorometry (Fig. 3B). However, the pseudo-spherical morphology 
and size between 300 and 500 nm of the IBs formed in MC4100, BW30270 and 
KPM335 were indistinguishable from each other (Fig. 5) and similar to IBs isolated from 
other E. coli strains (Garcia-Fruitos et al. 2010). 
The endotoxic activity of the IBs produced in E. coli strains MC4100, BW30270 and 
KPM335 was investigated using the HEK-Blue™ hTLR4 LPS detection assay. As 
shown in Figure 6, the hTLR4 stimulating activity of IBs from KPM335 was of several 
orders of magnitude lower compared with the ability of IBs from the wild-type strains to 
stimulate the hTLR4 signaling pathway. 
Apart from the highest specific fluorescent intensity and the extremely low endotoxic 
activity, IBs formed in KPM335 were indistinguishable from those obtained from its 
parental strain or the common MC4100 laboratory strain. However, we wanted to 
ensure that these particles still retained their ability to (i) mechanically stimulate the 
growth of mammalian cells when used as surface-decorating topographies in cell 
culture settings as described previously (García-Fruitós et al. 2009; Seras-Franzoso et 
al. 2013c; Diez-Gil et al. 2010; Tatkiewicz et al. 2013; Seras-Franzoso et al. 2013b), 
and (ii) release functional proteins when internalized by mammalian cells (Liovic et al. 
2012; Vazquez et al. 2012; Seras-Franzoso J et al. 2013; Seras-Franzoso et al. 
2013b). The comparative analysis of cell proliferation on IB-decorated surfaces 
revealed similar properties of all tested IBs (Figure 7). Noteworthy, the ability of 
KPM335 IBs to penetrate into mammalian cells with fluorescent activity was fully 
conserved (Fig. 8), thus confirming a similar molecular architecture, mechanical 
stability and cell penetrability of IBs from the endotoxin-free strain. In fact, penetrability 
of these IBs was slightly but significantly higher than that of conventional, wild-type IBs 
(p<0.05 when measuring fluorescence and p<0.01 when determining the percentage of 
uptaking cells). Taken together, IBs lacking endotoxic activity hold promise for their use 
in biomedical  applications (Garcia-Fruitos et al. 2012). 
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Discussion. 
E. coli is the most common cell factory for the production of recombinant proteins 
(Ferrer-Miralles and Villaverde 2013), including biopharmaceuticals for use in humans 
(Ferrer-Miralles et al. 2009). Like in other Gram-negative bacteria, the outer membrane 
of E. coli contains LPS as a main constituent that is released upon cell disruption to 
obtain intracellular products of biotechnological interest. In the human body, the LPS, 
also known as endotoxin, is a potent activator of inflammatory responses as it 
promotes the release of several of pro-inflammatory cytokines, which may cause high 
fever, severe tissue damage and death (Erridge et al. 2002). Therefore, many 
procedures for removal of LPS from recombinant protein preparations have been 
developed and adapted to specific processes to obtain products with different levels of 
purity (Magalhaes et al. 2007; Liu et al. 1997; Petsch and Anspach 2000). However, 
elimination of LPS requires considerable efforts and adds significant cost to 
downstream purification steps of proteins. 
Lately, E. coli and other cell factories are being used to produce protein products of 
potential use in medicine, that are more complex than soluble proteins, including phage 
components, virus like particles and diverse nanostructured protein materials such as 
fibers, regular nanoparticles and IBs (Rodriguez-Carmona and Villaverde 2010; 
Vazquez and Villaverde 2013; Neus Ferrer-Miralles et al. 2013). Being in general 
considered as waste materials in protein production processes, bacterial IBs have 
gained interest as they are formed by significant fractions of properly folded, functional 
polypeptides (Garcia-Fruitos et al. 2005; Garcia-Fruitos et al. 2012; Gonzalez-
Montalban et al. 2007). Due to their mechanical stability, the ability to penetrate 
mammalian cells in the absence of cellular damage and the release of functional 
protein, in a way similar to the release of functional hormones from amyloid repositories 
(Villaverde 2012), bacterial IBs became unexpectedly promising materials in drug 
delivery and in regenerative medicine (Garcia-Fruitos and Villaverde 2010; Liovic et al. 
2012; Talafova et al. 2013; García-Fruitós et al. 2009; Seras-Franzoso et al. 2012; 
Seras-Franzoso J et al. 2013; Seras-Franzoso et al. 2013c; Seras-Franzoso et al. 
2013b; Seras-Franzoso et al. 2013a; Tatkiewicz et al. 2013; Vazquez et al. 2012; 
Villaverde et al. 2012; Villaverde 2012). Although not determined quantitatively, 
contamination of IBs with bacterial LPS is a result of cell debris formation during cell 
disruption and separation (Neubauer et al. 2006; Georgiou and Valax 1999). Being 
highly porous and structurally more complex than soluble protein, LPS removal from 
IBs would necessarily pose technical problems. Here we have explored, as an 
alternative to commonly used LPS removal methods, the biofabrication of functional 
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IBs in a newly developed endotoxin-free E. coli strain. We were particularly interested 
in whether these IBs produced in an endotoxin-free E. coli strain would maintain their 
mechanical and biological properties as the bacterial LPS could be a structural 
component of IBs supporting their key properties as functional biomaterials.  
Here we show that, although the endotoxin-free strain KPM335 grew slower than the 
control strains (Fig. 1), the yield of the model protein produced in KPM335 was even 
slightly higher compared with the wild-type controls (Fig. 2). Remarkably, the specific 
fluorescence of VP1GFP deposited as IBs in KPM335 was significantly higher than in 
the wild-type strains (Fig. 3). This could be due to the lack of normal LPS as a 
contaminant in the material, which may result in a better protein folding with reduced 
quenching of fluorescence. Also, IBs from KPM335 adopted the pseudo-spherical 
geometry common in the material (Garcia-Fruitos et al. 2010), being morphologically 
indistinguishable from standard particles (Figs. 4 and 5). In the same context, 
endotoxin-depleted IBs used as topographies for mammalian cell proliferation (Seras-
Franzoso et al. 2013c) stimulated, as conventional IBs, cell spread (Fig. 7). This fact 
indirectly indicates that the LPS-free material has the same surface chemical properties 
and mechanical stability as wild-type protein particles and that LPS is not a structural 
element significantly contributing to the mechanical stability of the bacterial amyloids. 
Interestingly, the capability of LPS-free IBs to penetrate mammalian cells is slightly but 
significantly higher than that of the control material (Fig. 8B). Irrespective of the precise 
mechanism, this fact, together with their higher specific fluorescence (Fig. 3B), points 
out LPS-free IBs as valuable biocompatible materials for the delivery of protein drugs. 
On the other hand, among all bacterial cell factories (Ferrer-Miralles and Villaverde 
2013) and non-bacterial protein production hosts developed thus far (Corchero et al. 
2013), endotoxin-free E. coli strains seem to be an appealing alternative to minimize 
the biological risk of contaminations in the final products. This is especially relevant in 
the context of new systems biotechnology tools for this species (Lee et al. 2012) that 
further develops to become a true industrial factory, and makes biological fabrication of 
soluble proteins and nanostructured materials highly competitive with synthetic 
chemistry (Chen 2012; Vazquez and Villaverde 2013). 
In the context of potential applications of IBs in drug delivery either in vitro for 
regenerative medicine (Seras-Franzoso J et al. 2013), in vivo in oral administration 
(Vazquez et al. 2012) or envisaging transdermal or cell-targeted delivery (Talafova et 
al. 2013; Liovic et al. 2012), endotoxin-free IBs hold promise for the development 
towards a powerful tool that ensures both functionality and additional biosafety, being 
particularly attractive regarding cost-effective production and regulatory issues.  
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Figure legends 
Figure 1. Optical densities at 550 nm (OD550) of the cell suspensions of E. coli strains 
MC4100/pTr99a-VP1GFP, BW30270/pTr99a-VP1GFP and KPM335/pTr99a-VP1GFP 
3h post-induction of VP1GFP gene expression at different temperatures (37ºC, 25ºC 
and 16ºC).  
Figure 2. Amount of soluble and insoluble VP1GFP produced in E. coli strains 
MC4100/pTr99a-VP1GFP, BW30270/pTr99a-VP1GFP and KPM335/pTr99a-VP1GFP 
3 h post-induction of VP1GFP gene expression at different temperatures. 
Figure 3. Green fluorescence of soluble and insoluble fractions in VP1GFP-producing 
E. coli strains MC4100, BW30270 and KPM335 (A) and specific fluorescence of 
soluble and insoluble VP1GFP produced in MC4100, BW30270 and KPM335 (B) at 
different temperatures. 
Figure 4. Light microscopy images of VP1GFP-producing E. coli strains MC4100 (A), 
BW30270 (B), and KPM335 (C) 3h post-induction. Left to right: phase contrast 
microscopy at 100 X magnification; fluorescence microscopy at 100 X magnification; 
merged images using Image J software. 
 15 
Figure 5. Scanning electron micrographs of VP1GFP IBs isolated from E. coli strains 
MC4100 (left), BW30270 (middle) and KPM335 (right). 
 
Figure 6. Stimulation of the hTLR4 signaling pathway by IBs produced in E. coli strains 
MC4100, BW30270 and KPM335. Relative NF-κB induction was measured following 
stimulation of HEK-Blue hTLR4 cells with tenfold serial dilutions of IBs. 
 
Figure 7. Proliferation of 1BR3.G cells on matrices formed by IBs from E. coli strains 
MC4100, BW30270 and KPM335 at 37ºC monitored at several times after seeding.  
 
Figure 8. Internalization of IBs by HeLa cells. The HeLa cells were incubated with 5 µg 
of VP1GFP IBs from E. coli strains BW30270 and KPM335. Internalization of IBs was 
monitored by measuring the intensity of fluorescence inside the cells (A) and the 
fraction of fluorescent cells (B). 
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